BHV-1 vaccine induces cross-protection against BHV-5 disease in cattle

Construction and growth properties of bovine herpesvirus type 5 recombinants defective in the glycoprotein E or thymidine kinase gene or both

“…BoHV-1 and -5 show extensive serological cross-reactivity so that they cannot be distinguished by routine virus neutralization tests (32). In addition, it has been demonstrated that a BoHV-1 vaccine induced partial protection against a BoHV-5 virulent challenge in calves (13,14). Thus, the recombinants BoHV-5 gE∆, TK∆ and gE/TK∆ described herein represent potential vaccine candidates to prevent BoHV-1 and -5 associated diseases in South American countries.…”

“…Most of the vaccines marketed in South America contain inactivated BoHV-1 strains, which are not effective with respect to the cell immune response (13,14), and lack a serological marker, which is an important criterion for vaccination with differential vaccines (15). Some European countries have successfully eradicated BoHV-1 infection based on differential vaccines (12).…”

“…Some European countries have successfully eradicated BoHV-1 infection based on differential vaccines (12). Reports indicate that modified live BoHV-1 vaccines including the gE-deleted marker vaccines do not efficiently protect against BoHV-5 infections (13,14). Therefore, a better vaccine candidate for the protection against BoHV-5 infection is needed.…”

Prokaryotic expression of a truncated form of bovine herpesvirus 1 glycoprotein E (gE) and its use in an ELISA for gE antibodies

“…BoHV-1 and BoHV-5 are closely related genetically, antigenically and display an extensive serological cross-reactivity (Bratanich et al 1991, Vogel et al 2002, Delhon et al 2003, Del Medico Zajac et al 2006. Bovine herpesvirus type 1 is distributed worldwide -with the exception of some European countries that eradicated the infection -and is associated with a variety of clinical conditions, including respiratory disease (infectious bovine rhinotracheitis, IBR), reproductive system disease (vulvovaginitis or balanopostitis IPV/IBP) and abortions (Kahrs 2001).…”

“…Few vaccines contain BoHV-5 antigens in their formulation, none of them based on live virus (E.F. Flores, unpublished). The antigenic similarity and serological cross-reactivity between BoHV-1 and -5 has led to the assumption that vaccines containing either virus would confer protection upon homologous and heterologous virus challenge (Del Medico Zajac et al 2006, Brum et al 2010a, Anziliero et al 2011. Following the trend of North America and Europe, South American countries are now embarking on the development and use of BoHV-1 DIVA (for differentiating infected from vaccinated animals) vaccines (Brum et al 2010a).…”